The role of circular RNA in Diabetic Nephropathy.


Journal

International journal of medical sciences
ISSN: 1449-1907
Titre abrégé: Int J Med Sci
Pays: Australia
ID NLM: 101213954

Informations de publication

Date de publication:
2022
Historique:
received: 01 02 2022
accepted: 06 05 2022
entrez: 13 6 2022
pubmed: 14 6 2022
medline: 15 6 2022
Statut: epublish

Résumé

Diabetic nephropathy (DKD) is the most common chronic microvascular complication of diabetes. About 20%-40% of diabetics develop DKD, which eventually leads to chronic kidney failure. Although progress has been made in diagnosis and treatment tools, diabetic nephropathy is still a major clinical problem. In recent years, circular RNA (CircRNA) has become a research hotspot. CircRNA is a non-coding RNA formed by covalently closing the 5 'and 3' ends of the precursor RNA. CircRNA has powerful biological functions. CircRNA can regulate the expression of target genes through competitive binding with microRNA, thus playing the biological role of endogenous RNA (CeRNA). Many studies have shown that circRNAs plays an important role in malignant tumors, autoimmune system diseases, coronary heart disease and other diseases. More and more studies have shown that it can also be used as a biomarker of diabetes and diabetic nephropathy. This review summarizes the origin, classification, biogenesis and regulatory mechanisms of circRNAs. In addition, the pathogenesis and clinical significance of circRNAs as competing endogenous RNAs involved in diabetic nephropathy were also introduced. This will help us fully understand the pathological mechanism of diabetic nephropathy and develop new therapeutic targets or treatment options to improve the prognosis of patients with diabetic nephropathy.

Identifiants

pubmed: 35693742
doi: 10.7150/ijms.71648
pii: ijmsv19p0916
pmc: PMC9149631
doi:

Substances chimiques

Biomarkers 0
MicroRNAs 0
RNA, Circular 0
RNA 63231-63-0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

916-923

Informations de copyright

© The author(s).

Déclaration de conflit d'intérêts

Competing Interests: The authors have declared that no competing interest exists.

Références

J Cell Physiol. 2019 Nov;234(11):21249-21259
pubmed: 31087368
Eur Rev Med Pharmacol Sci. 2019 Oct;23(20):8771-8778
pubmed: 31696463
Sci Rep. 2016 Feb 04;6:20304
pubmed: 26842599
Diabetes Metab Syndr Obes. 2021 Feb 17;14:729-740
pubmed: 33628038
Diabetologia. 2014 Aug;57(8):1726-36
pubmed: 24908566
Sci Rep. 2017 Aug 24;7(1):9371
pubmed: 28839221
J Cardiovasc Pharmacol. 2022 Mar 08;:
pubmed: 35170486
Proc Natl Acad Sci U S A. 2019 Apr 9;116(15):7455-7464
pubmed: 30914462
Mol Cancer. 2020 Oct 14;19(1):149
pubmed: 33054773
Cell Rep. 2015 Jan 13;10(2):170-7
pubmed: 25558066
Exp Cell Res. 2018 Jul 15;368(2):147-158
pubmed: 29730164
Front Pharmacol. 2020 Mar 03;11:191
pubmed: 32194418
Nat Rev Nephrol. 2021 Dec;17(12):814-826
pubmed: 34381199
Gene. 2020 Jul 15;747:144661
pubmed: 32275999
Diabetes. 2018 Apr;67(4):552-553
pubmed: 29559513
J Clin Invest. 2019 Apr 29;129(6):2266-2278
pubmed: 31033478
Biochem Biophys Res Commun. 2017 Mar 11;484(3):598-604
pubmed: 28137588
J Diabetes Res. 2017;2017:2615286
pubmed: 28791309
Autoimmunity. 2022 Jun;55(4):254-263
pubmed: 35285770
Genome Biol. 2015 Jun 16;16:126
pubmed: 26076956
Diabetologia. 2021 Mar;64(3):681-692
pubmed: 33398455
Front Pharmacol. 2019 Apr 26;10:428
pubmed: 31080413
Mol Ther Nucleic Acids. 2019 Sep 6;17:636-643
pubmed: 31400606
Mediators Inflamm. 2018 Nov 5;2018:8515032
pubmed: 30524199
Trends Cell Biol. 2020 Mar;30(3):226-240
pubmed: 31973951
Oxid Med Cell Longev. 2019 Oct 3;2019:7495629
pubmed: 31687085
J Cell Physiol. 2020 May;235(5):4520-4529
pubmed: 31680239
J Cell Mol Med. 2020 Aug;24(15):8779-8788
pubmed: 32597022
Gene. 2019 Aug 15;709:1-7
pubmed: 31108165
MLO Med Lab Obs. 2017 Feb;49(2):20, 22
pubmed: 30005475
JAMA. 2016 Aug 9;316(6):602-10
pubmed: 27532915
Pharmacol Ther. 2018 Jul;187:31-44
pubmed: 29406246
J Cell Physiol. 2019 Feb;234(2):1469-1476
pubmed: 30054916
Gene. 2021 Jan 10;765:145076
pubmed: 32860899
J Cell Physiol. 2019 Aug;234(8):13807-13819
pubmed: 30663767
RNA Biol. 2017 Mar 4;14(3):361-369
pubmed: 28080204
Mol Cell. 2018 Aug 2;71(3):428-442
pubmed: 30057200
J Cell Mol Med. 2017 Jan;21(1):185-192
pubmed: 27561207
Mol Ther Nucleic Acids. 2021 Nov 10;26:1291-1302
pubmed: 34853728
Nat Rev Genet. 2019 Nov;20(11):675-691
pubmed: 31395983
BMC Endocr Disord. 2022 Mar 15;22(1):67
pubmed: 35291991
Diabetes. 2021 Feb;70(2):603-615
pubmed: 33472945
Aging (Albany NY). 2021 Mar 10;13(6):8467-8480
pubmed: 33714195
J Cell Mol Med. 2020 Jun;24(12):6523-6533
pubmed: 32333642
Oncol Res. 2018 Jan 19;26(1):103-110
pubmed: 28548636
Eur J Med Res. 2022 Apr 7;27(1):55
pubmed: 35392987

Auteurs

Chao Tu (C)

Department of Internal Medicine, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213000, China.

Liangzhi Wang (L)

Department of Internal Medicine, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213000, China.

Lan Wei (L)

Department of Internal Medicine, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213000, China.

Zhuyan Jiang (Z)

Department of Dermatology, Southwest Hospital, Army Military Medical University, Chongqing, 400038, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH